product name Oridonin
Description: Oridonin, a cell-permeable diterpenoid purified from Rabdosia rubescens, is a potent antitumor agent. Oridonin acts by targeting AE (AML1-ETO) oncoprotein. Exposure to oridonin induces apoptosis in AE-bearing leukemic cells through the activation of intrinsic apoptotic pathway and triggering a caspase-3-mediated degradation. Oridonin possesses anti NF-κB activity and displays antiproliferative (ED50 ~ 2.7 µg/ml in lymphoid malignant cells) and antiangiogenic properties (significantly inhibits network formation of HMEC-1 cells at 2.5 µg/ml).
References: Mol Cancer Ther. 2005 Apr;4(4):578-86.
C20H28O6
Formula
364.43
CAS No.
28957-04-2
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: > 10 mM
Water:
Ethanol:
Solubility (In vivo)
Synonyms
other peoduct :
| In Vitro |
In vitro activity: Oridonin is a cell-permeable diterpenoid compound that possesses anti NF-κB activity and displays antiproliferative (ED50 ~ 2.7 µg/ml in lymphoid malignant cells) and antiangiogenic properties (significantly inhibits network formation of HMEC-1 cells at 2.5 µg/ml). Reported to affect DNA synthesis, induce apoptosis and initiate cell cycle arrest. Shown to efficiently block both TNF-α and LPS-induced NF-κB activity in Jurkat and in RAW264.7 murine macrophages, and inhibit p65 NF-κB transcriptional activity (IC50 ~ 5 µg/ml in MT-1 cells) by disrupting NF-κB DNA-binding activity without interfering with its nuclear translocation. Kinase Assay: Cell Assay: |
|---|---|
| In Vivo | |
| Animal model | |
| Formulation & Dosage | |
| References | J. Nat. Prod. 67: 2-4, 2004; Mol. Cancer Ther. 4: 578-586, 2005. |
